| SMITH & NEPHEW PLC Form 6-K July 26, 2018 |
|---|
| UNITED STATES                             |
| SECURITIES AND EXCHANGE COMMISSION        |
| Washington, D.C. 20549                    |
|   |
| Form 6-K                                  |
|   |
| Report of Foreign Private Issuer          |
| Pursuant to Rule 13a-16 or 15d-16 of the  |
| Securities Exchange Act of 1934           |
|   |
| July 26, 2018                             |
|   |
| Commission File Number 001-14978          |
|   |
| SMITH & NEPHEW plc                        |
| (Registrant's name)                       |
|   |
| 15 Adam Street                            |
| London, England, WC2N 6LA                 |
| (Address of principal executive offices)  |
|   |

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

| Form 20-F                    | Form 40-F   |
|------------------------------|---|
| Indicate by check 101(b)(1). | mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule  |
| Yes                          | No  |
| Indicate by check 101(b)(7). | mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule  |
| Yes                          | No  |
|                              | mark whether the registrant by furnishing the information contained in this Form is also thereby ation to the Commission pursuant to Rule 12g3-2 (b) under the Securities Exchange Act of 1934. |
| Yes                          | No  |
| If "Yes" is marked n/a.      | d, indicate below the file number assigned to the registrant in connection with Rule 12g3-2 (b): 82-  |
|                              |   |
|                              |   |

| Smith & Nephew plc   |
|--|
| INDEX TO EXHIBITS  |
| Item 1. Press release entitled "Smith & Nephew Second Quarter and First Half 2018 Results", dated July 26, 2018. |
|  |

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Smith & Nephew plc (Registrant)

Date: July 26, 2018 By: /s/ Susan Swabey

Susan Swabey Company Secretary

Smith & Nephew Second Quarter and First Half 2018 Results

Q2 revenue growth of 4% reported and 2% underlying Full year guidance reconfirmed

26 July 2018

Smith & Nephew (LSE:SN, NYSE:SNN), the global medical technology business, reports results for the second quarter and first half ended 30 June 2018:

|                                     | Reported<br>30 June<br>2018<br>\$m | 1 July<br>2017<br>\$m | Reported growth | Trading2<br>30 June<br>2018<br>\$m | 1 July<br>2017<br>\$m | Underlying growth % |
|-------------------------------------|------------------------------------|-----------------------|-----------------|------------------------------------|-----------------------|---------------------|
| Second Quarter Results1             |                                    |                       |                 |                                    |                       |                     |
| Revenue                             | 1,245                              | 1,194                 | 4               | 1,245                              | 1,194                 | 2                   |
| First Half Results 1 Revenue        | 2,440                              | 2,336                 | 4               | 2,440                              | 2,336                 | 1                   |
| Operating profit                    | 372                                | 414                   | ·               | 2,110                              | 2,330                 | 1                   |
| Trading profit                      |                                    |                       |                 | 507                                | 493                   |                     |
| Operating/trading profit margin (%) | 15.3                               | 17.7                  |                 | 20.8                               | 21.1                  |                     |
| EPS/ EPSA (cents)                   | 31.4                               | 37.0                  |                 | 43.7                               | 43.0                  |                     |

Namal Nawana, Chief Executive Officer, said:

"In my first few weeks at Smith & Nephew I have reviewed our businesses and operations and validated that we have an excellent product portfolio with numerous best-in-class medical technologies. We are now focused on energising and organising the business to accelerate growth."

#### Second Quarter Highlights1

- · Q2 reported revenue growth of 4%, including 2% FX tailwind, with underlying growth of 2%
- · Established Markets returned to growth, with improved dynamics across Hip and Knee Implants and strong performance from Sports Medicine and Advanced Wound Devices
- · Emerging Markets up 6%; double digit China growth offset by lower level of Middle East tenders

<sup>&</sup>quot;We delivered 4% reported and 2% underlying growth in the quarter. We reconfirm our full year guidance.

#### First Half Highlights1

- · H1 reported revenue growth of 4%, including 3% FX tailwind, with underlying revenue up 1%
- o Trading profit margin down 30bps, in line with guidance
- o Operating profit margin down 240bps, reflecting \$58 million costs of APEX programme
- · APEX programme on track, with actions undertaken in H1 which will deliver more than \$50 million of annualised benefits
- Trading cash flow of \$387 million, up from \$327 million in 2017, with higher trading profit to cash conversion ratio of 76% (2017: 66%)
- · Adjusted earnings per share (EPSA) up 2% to 43.7¢, reflecting improved trading (EPS 31.4¢; 2017 37.0¢)
- · Interim dividend of 14.0¢ per share, in-line with our progressive dividend policy (2017: 12.3¢)

#### Full year guidance unchanged

- · Underlying revenue growth expected to be in the range 2-3% with a trading profit margin at or above that achieved in 2017
- Tax rate on trading results expected to be within the range of 20-21% barring changes to tax legislation or other one-off items

### Analyst conference call

An analyst meeting and conference call to discuss Smith & Nephew's second quarter trading and first half 2018 results for the period ended 30 June 2018 will be held today, Thursday 26 July at 9:00am BST / 4:00am EDT. This will be webcast live and available for replay shortly after. The details can be found on the Smith & Nephew website at <a href="https://www.smith-nephew.com/results">www.smith-nephew.com/results</a>.

### Enquiries

ndreq Investors Andrew Swift +44 (0) 20 7960 2285 Smith & Nephew

Media Charles Reynolds +44 (0) 20 7401 7646 Smith & Nephew